|Last Price$8.95||Day Change (%)0.56%|
|Open Price$9.00||Day Change ($)0.05|
|Day Range8.72–9.00||52-Week Range6.00–13.18|
As of Thu 9/29/2016 5:00:00 PM | USD
Cytokinetics' CYTK ispinesib trial results for head and neck cancer did not yield a statistically significant change in its patients. We are leaving our fair value estimate at $3.50 per share, as we had already assigned a low probability of success for this indication. Our more conservative ...
Cytokinetics faces challenging odds.